Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

87.37 +1.29 (+1.50%)
Official Closing Price Updated: 7:00 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma
From Merck & Co., Inc.
Via Business Wire
These Are the 5 Worst-Performing Stocks in the Dow Jones Industrial Average With 2024 Almost Over
Via The Motley Fool
Topics Stocks
NYSE:MRK stands out as a stock that provides good value for the fundamentals it showcases.
Despite its impressive fundamentals, MERCK & CO. INC. (NYSE:MRK) remains undervalued. 
Via Chartmill
AstraZeneca-Merck Partnered Lynparza Shows Long-Term Survival With Reduced Death Risk Of 28% In Breast Cancer Patients
AstraZeneca and Merck report Lynparza's significant survival benefits in high-risk breast cancer and Keytruda combo results in ovarian cancer. 
Via Benzinga
Merck & Co Unusual Options Activity For December 02
 
Via Benzinga
Why NYSE:MRK provides a good dividend, while having solid fundamentals.
Why the dividend investor may take a look at MERCK & CO. INC. (NYSE:MRK). 
Via Chartmill
LYNPARZA® (olaparib) Demonstrated Clinically Meaningful Prolonged Survival Benefit in Early Breast Cancer in OlympiA Phase 3 Trial
From Merck & Co., Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Merck Reveals Mixed Data From Keytruda/Lynparza Regime In Ovarian Cancer
Merck's ovarian cancer trial met its primary endpoint, while lymphoma trial data set the Phase 3 dose for zilovertamab vedotin at 1.75 mg/kg. 
Via Benzinga
Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced Epithelial Ovarian Cancer
From Merck & Co., Inc.
Via Business Wire
Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
From Merck & Co., Inc.
Via Business Wire
2 Healthcare Dividend Stocks to Hold for the Long Haul
Via The Motley Fool
Why Summit Therapeutics Stock Rocketed 6% Higher on Friday
Via The Motley Fool
Merck and Ridgeback Biotherapeutics Announce Initiation of Phase 3 Study (MOVe-NOW) Evaluating LAGEVRIO™ (molnupiravir) for the Treatment of COVID-19 in High-Risk Adults
From Merck & Co., Inc.
Via Business Wire
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
Unsurprisingly, these stock pickers are capitalizing on an opportunity that's only recently become addressable. 
Via The Motley Fool
3 Ultra-Cheap Dividend Stocks to Buy in December
Via The Motley Fool
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market. 
Via Benzinga
FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations
From Merck & Co., Inc.
Via Business Wire
The Smartest Dividend Stocks to Buy With $3,000 Right Now
They may not offer the very highest yields, but their dividends are built to last, and even grow. 
Via The Motley Fool
The Data Shows Three Market-Jolting Forces On The Move
What we saw in the inflation data, income and spending-related reports points to a couple of big moves we need to start making now. 
Via Talk Markets
Topics Economy Stocks / Equities
Merck to Participate in the Citi 2024 Global Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Why Is Merck Stock Trading Higher On Monday?
Merck's ZENITH trial shows Winrevair significantly lowers morbidity or mortality risk in PAH patients, building on earlier Phase 3 STELLAR results. 
Via Benzinga
Merck Announces Pivotal Phase 3 ZENITH Trial Evaluating WINREVAIR™ (sotatercept-csrk) Met Primary Endpoint at Interim Analysis
From Merck & Co., Inc.
Via Business Wire
Merck Recommends Rejection of TRC Capital’s “Mini-Tender” Offer
From Merck & Co., Inc.
Via Business Wire
Merck to Participate in the 7th Annual Evercore ISI HealthCONx Conference
From Merck & Co., Inc.
Via Business Wire
Merck’s WELIREG® (belzutifan) Approved in China for the Treatment of Adult Patients With Certain Types of Von Hippel-Lindau (VHL) Disease-Associated Tumors
From Merck & Co., Inc.
Via Business Wire
Surendralal Karsanbhai Elected to Merck Board of Directors
From Merck & Co., Inc.
Via Business Wire
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
Pyxis Oncology announces mixed Phase 1 PYX-201 data, collaboration with Merck, and analyst downgrade citing limited efficacy beyond head-and-neck cancer. 
Via Benzinga
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
Via The Motley Fool
Merck Data at the ASH 2024 Annual Meeting Highlights Promising Hematology Pipeline With Diverse Range of Investigational Assets and Novel Modalities
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.